Posted by Michael Wonder on 31 May 2020
Johnson & Johnson receives positive CHMP opinion for Janssen’s investigational preventive Ebola vaccine regimen
29 May 2020 - The investigational Ebola vaccine regimen leverages Janssen’s established AdVac and PER.C6 technologies and Bavarian Nordic’s MVA-BN technology.
Johnson & Johnson today announced that its Janssen Pharmaceutical Companies received a positive opinion from the CHMP of the EMA for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species.
Two marketing authorisation applications were submitted to the EMA in support of the vaccines in the two-dose regimen (Ad26.ZEBOV, MVA-BN-Filo).
